NEWS
Consultation on ‘silent pandemic’ of AMR
The Department of Health and Social Care has launched a consultation to protect patients from the ‘silent pandemic’ of increasing antimicrobial resistance (AMR). The consultation brings together the latest evidence and data from leading experts on AMR, and will help inform a new five-year national action plan. Prof. Dame Sally Davies, UK Special Envoy on AMR, said: “Antimicrobial resistance may be the defining health challenge of this century. I am proud of the UK’s efforts on research and development, stewardship, surveillance and international engagement across all sectors. I hope that our next national action plan will show that we can learn from the COVID-19 pandemic and collaborate to step up our actions.” A report published by the UK Health Se- curity Agency (UKHSA) showed there were more than 50,000 severe antibiotic-resistant infections in England last year including bloodstream infections, skin infections, surgi- cal site infections and skin and soft tissue infections.
Vaccination offers protection against
The report also found the number of severe antibiotic resistant infections rose by 2.2.% in England compared to 2020, the equivalent of 148 infections per day. The new five-year national action plan will form the next stage of the 20-year AMR strategy, published in 2019. This consul- tation will seek views to ensure that the next five-year plan – continuing up until 2029 – is informed by the most up-to-date evidence. Visit: https://consultations.dhsc.
gov.uk/63725c92d095d9316852519c
£100m programme to transform care for people living with chronic lung conditions
LifeArc is launching a landmark £100m programme to urgently develop new healthcare solutions for the more than 300,000 people living with bronchiectasis and cystic fibrosis in the UK. Dr. Catherine Kettleborough, who leads the LifeArc Chronic Respiratory Infection Translational Challenge, commented that Bronchiectasis and cystic fibrosis are “challenging conditions which cause enormous disruption to people’s lives, significantly reduce quality of life and
ultimately shorten lives.”
The programme aims to accelerate scientific innovation and develop new diagnostics, therapies and technologies to transform how chronic lung infections are detected, treated and managed. It is part of LifeArc’s strategy to invest £1.3bn by 2030 to solve some of the most complex and challenging healthcare problems, including by launching Translational Challenges in underfunded and under supported disease areas.
monkeypox New UK Health Security Agency (UKHSA) evidence indicates that a single MVA-BN vaccine dose provides around 78% protection against monkeypox 14 days after being vaccinated. This is the strongest UK evidence yet for the effectiveness of the vaccine. As part of the analysis, monkeypox cases in England and vaccination uptake data between 4 July to 3 November 2022 were reviewed to estimate vaccine effectiveness within the eligible gay, bisexual and men who have sex with men (GBMSM) cohort, with vaccine coverage among cases compared to the wider eligible population. Out of 363 monkeypox cases in this period, 8 had been vaccinated at least 14 days before and 32 had been vaccinated between 0 to 13 days before. The rest (323) were not vaccinated during this outbreak. This gives an estimate of vaccine effectiveness for a single dose of 78% 14 or more days after vaccination. The UKHSA will continue to investigate the duration of protection from a single dose and the combined protection of 2 doses. Jamie Lopez-Bernal, consultant epidemiologist at UKHSA, said: “While monkeypox cases are low it remains vital to stay alert to the risks. Thank you to everybody who has come forward for their vaccine already – it is helping to keep numbers low, but we can’t get complacent. We now know that a single vaccine dose provides strong protection against monkeypox, which shows just how important vaccination is to protect yourself and others. A second dose is expected to offer even greater and longer lasting protection.”
12 l
WWW.CLINICALSERVICESJOURNAL.COM
JANUARY 2023
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
